May 06, 2021
VIRALEZE™ launches in Europe (ASX Announcement)
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that VIRALEZE™ antiviral nasal spray is now available for purchase by consumers in Europe via Starpharma’s www.viraleze.co webstore.
VIRALEZE™ is already available in the UK through LloydsPharmacy’s 1,400 stores and online and is expected to be available via independent UK pharmacies later this month.
VIRALEZE™ is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013), which is virucidal, irreversibly inactivating >99.9% of coronavirus/SARS-CoV-2 within one minute. These antiviral studies were conducted at the renowned Scripps Research Institute in the US and a number of other specialist virology laboratories.
The active in VIRALEZE™ (SPL7013) has demonstrated potent antiviral activity against multiple strains of SARS-CoV-2 as well as other respiratory viruses, including cold viruses, influenza, RSV (respiratory syncytial virus), MERS, and SARS.
The antiviral active in VIRALEZE™ (SPL7013) works by irreversibly blocking coronavirus SARS-CoV-2 ‘spike’ proteins from binding to human airway cells.
VIRALEZE™ antiviral nasal spray forms a physical barrier to respiratory viruses in the nasal cavity and has multiple unique advantages, including its virucidal action, its rapid onset (inactivates >99.9% SARS-CoV-2 within one minute, in laboratory studies1) and its ability to inactivate virus either before or after exposure1.
Dr Jackie Fairley, CEO of Starpharma commented: “We are delighted to be rolling out VIRALEZE™ in Europe following the UK launch. The product has been very well received in the UK, and we hope that VIRALEZE™ will provide European consumers with added peace of mind.”
“In addition to making VIRALEZE™ available direct to consumers in Europe via www.viraleze.co, commercial discussions for distribution continue in parallel. Starpharma is actively engaged in discussions with a variety of organisations in the region, including sporting teams, which have expressed interest in VIRALEZE™.”
VIRALEZE™ is registered in the EU. Starpharma is pursuing avenues to provide rapid access to VIRALEZE™ in India, including opportunities for expedited registration and distribution in the region. The Company is also progressing regulatory activities for a number of markets, including Australia, with the intention to roll it out across multiple markets.
For more information on VIRALEZE™ visit www.viraleze.co.
About VIRALEZE™ Antiviral Nasal Spray
VIRALEZE™ Antiviral Nasal Spray was developed by Starpharma (ASX: SPL) and is registered for sale in Europe. It is an easy-to-use antiviral nasal spray containing 1% w/w astodrimer sodium (SPL7013), shown in laboratory studies to inactivate respiratory viruses, including >99.9% of coronavirus SARS-CoV-2.
VIRALEZE™ binds to and irreversibly inactivates a broad spectrum of respiratory viruses. Inactivated viruses are blocked from attaching to cells inside your nose and taking hold. In addition to providing a protective antiviral barrier, VIRALEZE™ provides a moisturising layer to help keep nasal tissue hydrated, protecting it from dryness and damage.
SPL7013 is included in products that are already approved in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia, and New Zealand.
VIRALEZE™ can be used alongside vaccines, masks, and physical distancing.
Advantages of VIRALEZE™
- Broad-spectrum, works against multiple strains of SARS-CoV-2 and multiple respiratory viruses.
- Potent antiviral activity against multiple strains of SARS-CoV-2.
- Virucidal, irreversibly and rapidly inactivating >99.9% of coronavirus/ SARS‑CoV‑2 within one minute.
- Ability to inactivate virus either before or after exposure.
- Contains a well-tolerated, already marketed active, which is not absorbed into the bloodstream.
- Provides a moisturising and protective barrier to help keep nasal tissue hydrated.
- Room temperature storage, easy and convenient for regular use.
Starpharma acknowledges the $1 million in funding for the development of VIRALEZE™ provided by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest. Delivered by MTPConnect, the Australian Government's BTB program is a $22.3 million MRFF initiative that provides up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality.